Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 8/20 | 1.00 |
| ▸ | GRM2 | Q14416 | 4/20 | 1.00 |
| ▸ | GRM3 | Q14832 | 4/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 4/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 4/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 3/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 1.00 |
| ▸ | GRM8 | O00222 | 2/20 | 1.00 |
| ▸ | GRM6 | O15303 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | GRM5 | P41594 | 1/20 | 1.00 |
| ▸ | MTOR | P42345 | 1/20 | 1.00 |
| ▸ | GRM1 | Q13255 | 1/20 | 1.00 |
| ▸ | PLCB1 | Q9NQ66 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4835874 | 1.00 | GRM4 (1.00) | GRM4GRM2GRM3CYP1A2CYP2C19 | |
| SCHEMBL3125919 | 1.00 | GRM4 (1.00) | GRM4GRM2GRM3CYP1A2CYP2C19 | |
| SCHEMBL935371 | 1.00 | GRM4 (1.00) | GRM4GRM2GRM3CYP1A2CYP2C19 | |
| SCHEMBL481144 | 1.00 | GRM4 (1.00) | GRM4GRM2GRM3CYP1A2CYP2C19 | |
| SCHEMBL719389 | 1.00 | GRM4 (1.00) | GRM4GRM2GRM3CYP1A2CYP2C19 | |
| SCHEMBL2157698 | 1.00 | GRM4 (1.00) | GRM4GRM2GRM3CYP1A2CYP2C19 | |
| SCHEMBL235442 | 1.00 | GRM4 (1.00) | GRM4GRM2GRM3CYP1A2CYP2C19 | |
| SCHEMBL2916853 | 0.88 | GRM4 (0.78) | GRM4GRM2GRM3CYP1A2CYP2C19 | |
| SCHEMBL4835681 | 0.88 | GRM4 (0.78) | GRM4GRM2GRM3CYP1A2CYP2C19 | |
| SCHEMBL7271016 | 0.88 | GRM4 (0.78) | GRM4GRM2GRM3CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 508 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11938106-B2 | Treatment of tinnitus using glutamate receptor agonists | NORTHEAST OHIO MEDICAL UNIVERSITY (US) | 2024-03-26 | — | — | US | claimed |
| WO-2023097186-A1 | COMPOSITIONS AND METHODS FOR ENHANCING VISUAL FUNCTION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-06-01 | — | — | WO | claimed |
| US-20230038631-A1 | TREATMENT OF TINNITUS USING GLUTAMATE RECEPTOR AGONISTS | NORTHEAST OHIO MEDICAL UNIV (US) | 2023-02-09 | — | — | US | claimed |
| US-11304917-B2 | Treatment of tinnitus using glutamate receptor agonists | NORTHEAST OHIO MEDICAL UNIVERSITY (US) | 2022-04-19 | — | — | US | claimed |
| US-20110263652-A1 | Treatment and/or Prevention of Inner Ear Conditions by Modulation of a Metabotropic Glutamate Receptor | HOUSE EAR INSTITUTE (US) | 2011-10-27 | — | — | US | claimed |
| EP-2344151-A2 | TREATMENT AND/OR PREVENTION OF INNER EAR CONDITIONS BY MODULATION OF A METABOTROPIC GLUTAMATE RECEPTOR | HOUSE EAR INSTITUTE (US) | 2011-07-20 | — | — | EP | claimed |
| WO-2010048095-A2 | TREATMENT AND/OR PREVENTION OF INNER EAR CONDITIONS BY MODULATION OF A METABOTROPIC GLUTAMATE RECEPTOR | HOUSE EAR INSTITUTE (US) | 2010-04-29 | — | — | WO | claimed |
| EP-0797442-B1 | TREATMENT OF OPTIC NEURITIS | MASSACHUSETTS EYE & EAR INFIRM (US) | 2003-05-21 | — | — | EP | claimed |
| EP-1038023-A1 | AGONISTS OF METABOTROPIC GLUTAMATE RECEPTORS AND USES THEREOF | THE UAB RESEARCH FOUNDATION (US) | 2000-09-27 | — | — | EP | claimed |
| US-6013672-A | ADMINISTERING TO AN INDIVIDUAL SUFFERING FROM HEAD, SPINAL CORD TRAUMA, STROKE AND EPILEPSY A THERAPEUTICALLY EFFECTIVE DOSE OF A METABOTROPIC GLUTAMATE RECEPTOR AGONIST | UAB RESEARCH FOUNDATION (US) | 2000-01-11 | — | — | US | claimed |
| US-6001581-A | Cation-based bioassay using human metabotropic glutamate receptors | SIBIA NEUROSCIENCES, INC. (US) | 1999-12-14 | — | — | US | claimed |
| WO-1999031268-A1 | AGONISTS OF METABOTROPIC GLUTAMATE RECEPTORS AND USES THEREOF | UAB RESEARCH FOUNDATION (US) | 1999-06-24 | — | — | WO | claimed |
| US-5607973-A | Method of treating traumatic CNS tissue injury with a metabotropic glutamate receptor agonist | THERIAULT ELIZABETH (CA) | 1997-03-04 | — | — | US | claimed |
| WO-1997001332-A1 | METABOTROPIC GLUTAMATE RECEPTOR AGONISTS FOR THE TREATMENT OF TRAUMATIC CNS-TISSUE | THERIAULT ELIZABETH (CA) | 1997-01-16 | — | — | WO | claimed |
| US-20260036593-A1 | DEFECTIVE CALCIUM SIGNALING AS A TOOL IN AUTISM SPECTRUM DISORDERS | UNIV CALIFORNIA (US) | 2026-02-05 | — | — | US | disclosed |
| US-12029708-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-20240159774-A1 | DEFECTIVE CALCIUM SIGNALING AS A TOOL IN AUTISM SPECTRUM DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2024-05-16 | — | — | US | disclosed |
| EP-0518530-A2 | Improvements in or relating to excitatory amino acid receptor antagonists | ELI LILLY AND COMPANY (US) | 1992-12-16 | — | — | EP | disclosed |
| WO-1992021337-A1 | METHODS OF TREATING INJURY TO THE CENTRAL NERVOUS SYSTEM | GENSIA, INC. (US) | 1992-12-10 | — | — | WO | disclosed |
| US-5153196-A | Administering for reduction of neurotransmission in nervous system disorders | ELI LILLY AND COMPANY (US) | 1992-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12029708-B2 | Alkoxy compounds for disease treatment | ALDH1A2, CLN6, AGER | GRM4 2064/4885GRM2 1183/4885GRM3 841/4885 |
| US-20260036593-A1 | DEFECTIVE CALCIUM SIGNALING AS A TOOL IN AUTISM SPECTRUM DISORDERS | CASR, ORAI1, TRPC3 | GRM4 1953/4885GRM2 1791/4885GRM3 1333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.